| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | birinapant | CTRPv2 | pan-cancer | AAC | 0.0039 | 0.9 |
| mRNA | GSK269962A | GDSC1000 | pan-cancer | AAC | 0.0033 | 0.9 |
| mRNA | SB 505124 | GDSC1000 | pan-cancer | AAC | 0.0034 | 0.9 |
| mRNA | CMK | GDSC1000 | pan-cancer | AAC | -0.0055 | 0.9 |
| mRNA | UNC0638 | GDSC1000 | pan-cancer | AAC | 0.0029 | 0.9 |
| mRNA | Irinotecan | FIMM | pan-cancer | AAC | -0.013 | 0.9 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0033 | 0.9 |
| mRNA | GNF-2 | GDSC1000 | pan-cancer | AAC | -0.0053 | 0.9 |
| mRNA | Repligen 136 | CTRPv2 | pan-cancer | AAC | -0.0035 | 0.9 |
| mRNA | KIN001-266 | GDSC1000 | pan-cancer | AAC | -0.0032 | 0.9 |